PolitiKit

Securing a renewal of dedicated funding for mental health and addiction services via bilateral health agreements with provinces and territories ahead of the 2026 federal budget.

Discussion in regards to the legal and regulatory framework for governing charities, and grant contribution reform initiatives and ensuring that funding is allocated to these areas

Discussion in regards to the development and implementation of the Housing Builds including prevention strategies for homelessness, innovation, and programmatic supports.

Discussions on financial measures, policies, programs and sectoral tables to help the the charitable sector and community service charities to adapt and modernize. Funding to support the charitable sector including service continuity and adaption, and labour shortages.

The CMA is advocating that the trade of medical goods and medications be protected to avoid disruptions to patient care. Specifically, that the government: Continue to ensure pharmaceutical products and medical devices are not included in any countermeasures on tariffs. Improve safeguards for Canadian health data. Improve labour mobility so physicians can work across the country. Make it easier for qualified physicians to immigrate and work in Canada, including by fast-tracking immigration steps for US physicians.

MEDICAL MIS/DISINFORMATION: Provide CMA’s perspective on the impacts of medical misinformation and disinformation, including on public trust in science, medicine, and public health experts.

BUDGET: Provide CMA’s perspective on the Government of Canada’s budget, particularly as it relates to modernizing Canada’s health care system by enhancing efficiency, driving innovation, and promoting equitable access to care.

DIGITAL HEALTH: Increased investment in providing digital, virtual and telehealth services.

FEDERAL HEALTH FUNDING FOR A NEW PRIMARY CARE ACCESS FUND: Recommendation for a funding commitment to ensure that every Canadian has access to a family doctor or primary care team.

ADMINISTRATIVE BURDEN: Advocate for measures to alleviate the administrative burden on physicians and support their professional wellbeing, including investment to facilitate the development of EHRs and EMRs in Canada, improved remuneration for the completion of federal health forms, ensuring that physicians are not captured in the definition of "promoters" in the Disability Tax Credit Promoters Restrictions Regulations, and advocacy on discontinuing the requirement that employees present sick notes to their employers.

INDIGENOUS HEALTH AND RECONCILIATION WITH INDIGENOUS PEOPLES: Implementation of the Calls to Action of the Truth and Reconciliation Commission, including addressing the ongoing structural inequities that marginalize Indigenous Peoples, advancing the inclusion of Indigenous Peoples in societal systems and sectors, including health systems, and committing to collaborative and respectful relationships with Indigenous patients and communities. The CMA is also advocating to increase trust between Indigenous patients and health care providers, and to eliminate racism, inequitable access to care, and the ongoing harm caused to those within Canada’s health care system.

The CMA is advocating that the trade of medical goods and medications be protected to avoid disruptions to patient care. Specifically, that the government: Continue to ensure pharmaceutical products and medical devices are not included in any countermeasures on tariffs. Improve safeguards for Canadian health data. Improve labour mobility so physicians can work across the country. Make it easier for qualified physicians to immigrate and work in Canada, including by fast-tracking immigration steps for US physicians.

INTEGRATED HEALTH HUMAN RESOURCES Advocate for an Integrated Health Human Resources Strategy, including creating retention incentives and addressing administrative burden for health care professionals, increasing the number of doctors and nurses and ensuring that every Canadian has access to a family doctor or primary health team, increasing access to virtual care, creating an action plan to get internationally trained health care professionals to work, improving workforce data collection across health systems and investing in a supply needs-based planning tool, and facilitating team-based health care.

BUDGET: Provide CMA’s perspective on the Government of Canada’s budget, particularly as it relates to modernizing Canada’s health care system by enhancing efficiency, driving innovation, and promoting equitable access to care.

DIGITAL HEALTH: Increased investment in providing digital, virtual and telehealth services.

MEDICAL MIS/DISINFORMATION: Provide CMA’s perspective on the impacts of medical misinformation and disinformation, including on public trust in science, medicine, and public health experts.

FEDERAL HEALTH FUNDING FOR A NEW PRIMARY CARE ACCESS FUND: Recommendation for a funding commitment to ensure that every Canadian has access to a family doctor or primary care team.

INDIGENOUS HEALTH AND RECONCILIATION WITH INDIGENOUS PEOPLES: Implementation of the Calls to Action of the Truth and Reconciliation Commission, including addressing the ongoing structural inequities that marginalize Indigenous Peoples, advancing the inclusion of Indigenous Peoples in societal systems and sectors, including health systems, and committing to collaborative and respectful relationships with Indigenous patients and communities. The CMA is also advocating to increase trust between Indigenous patients and health care providers, and to eliminate racism, inequitable access to care, and the ongoing harm caused to those within Canada’s health care system.

Free trade agreements as they relate to the biopharmaceutical industry.

Policy measures to ensure security of drug supply in Canada and preserve Canada's attractiveness for biopharmaceutical launches, including in response to foreign pricing regulations.

Policies and frameworks to accelerate access to innovative medicines post-Health Canada approval, including efforts to reduce time-to-reimbursement and streamline federal/provincial listing processes.

Pharmaceutical pricing policy issues arising from the jurisdiction of the Patended Medicines Prices Review Board (PMPRB) and R&D reporting.

Policies and frameworks to accelerate access to innovative medicines post-Health Canada approval, including efforts to reduce time to reimbursement and streamline federal/provincial listing processes.

Common Drug Review Policies as it relates to reimbursement recommendation decision-making process and framework.

Any and all free trade treaty agreements as it relates to the North American Free Trade Agreement (NAFTA) and trade negotiations between Canada as it relates to the European Union, India, Japan and the Trans-Pacific Partnership. International trade policies in support of the biopharmaceutical industry, including competitive and predictable intellectual property protection, product regulation and patient access to medicines.

Free trade agreements as they relate to the biopharmaceutical industry

Policies and frameworks to accelerate access to innovative medicines post-Health Canada approval, including efforts to reduce time-to-reimbursement and streamline federal/provincial listing processes

Canada's Drug Agency policies as it relates to reimbursement recommendation decision-making process and framework

Pharmaceutical pricing policy issues arising from the jurisdiction of the Patented Medicines Prices Review Board (PMPRB)

Patented Medicine Prices Review Board (PMPRB) Guidelines with regard to prices charged by Rights Holders for patented medicines sold in Canada.

Communications regarding opportunities to speed patient access to live-saving medicines on publicly-funded drug formularies in Canada by reducing red tape.

Engagement with Health Canada’s Regulatory Operations & Enforcement branch regarding supply chain resilience & integrity; mitigating and alleviating drug shortages.

Pharmaceutical pricing policy considerations within the mandate of the Patented Medicine Prices Review Board (PMPRB), including regulatory amendments and associated guidance.

Canada’s Drug Agency policy frameworks and processes related to reimbursement recommendations, including decision?making approaches and timelines.

Engagement on federal policies and frameworks that support improved coordination across jurisdictions to facilitate timely patient access following Health Canada approval.

Policy measures to ensure security of drug supply in Canada and preserve Canada’s attractiveness for biopharmaceutical launches, including in response to foreign pricing regulations

Policies and frameworks to accelerate access to innovative medicines post-Health Canada approval, including efforts to reduce time-to-reimbursement and streamline federal/provincial listing processes

Canada's Drug Agency (CDA) policies as it relates to health economics assessment and recommendations made on new medicines.

Innovation Agenda, particularly with respect to initiatives to support and attract investments in the life sciences sector

Free Trade agreements as they relate to the biopharmaceutical industry

Food and Drug regulations as it relates to data protection and the regulation and protection of biopharmaceutical products

Policy measures to ensure security of drug supply in Canada and preserve Canada's attractiveness for biopharmaceutical launches, including in response to foreign pricing regulations

Mass investment in public programs that employ people doing the essential work of retrofitting our homes, operating rapid transit, restoring natural ecosystems, building a 100% renewable powered grid, and other critical work.

A legislated roadmap to achieve 100% affordable, reliable, renewable power for all by 2035 by strengthening clean energy regulations.

Maximum resourcing and direct support for Indigenous-owned and Indigenous-led renewable energy projects.

Binding emissions reduction targets, an ambitious emissions cap, and a robust plan to rapidly transition us off fossil fuels that are poisoning our planet and our health.

Ensure timely access to a comprehensive range of medicines, vaccines and related treatments and protect access to clinical trials, while helping to rebuild domestic capacities to develop and make drugs and vaccines.

Ensure patient organizations are consulted and provide feedback on policies, processes, patient representation and other initiatives from Canada's Drug Agency.

Learn more about and provide feedback on plans around COVID-19 vaccines, including protein based ones.

Recommend that the government and regulators adopt proactive approaches to communicating drug supply and shortages issues and measures to address them.

Provide input on pharmacare.

Support input regarding Canada’s pharmaceutical sovereignty.

Provide input on a national strategy for drugs for rare diseases.

Provide input on the government's response to tariffs and other trade measures as they relate to pharmaceuticals and related treatments, including their ingredients, as well as other health products and devices. Also recommend providing financial relief to patients impacted by price increases.

Support input into the consultation on draft guidance on decentralized clinical trials.